Feedback II – The GVAX Cancer Vaccine Trial at the Dana Farber
The GVAX cancer vaccine clinical trial, which has been opened in January 2006 is no more recruiting new patients. When it was open it recruited in addition to Alveolar Soft Part Sarcoma also Clear Cell Sarcoma, Renal Cell Carcinoma and Melanoma patients. In June 2007 I shared with you an e-mail from a parent whose […]
A Press Release – ARQ197
ArQule Achieves Clinical Milestone in MiT Trial with ARQ 197 Thursday October 2, 8:01 am ET Confirmed tumor response in clear cell sarcoma leads to expanded trial WOBURN, Mass.–(BUSINESS WIRE)–ArQule, Inc. (NASDAQ: ARQL – News) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of […]
Research sponsored by iCureASPS published: Is ASPS a target for Halofuginone therapy?
Cure Alveolar Soft Part Sarcoma International is very proud to announce the publication of a study that was supported by donations through our organization. The new study appears in the scientific journal â€Neoplasiaâ€. It focuses on genes which are expressed in alveolar soft part sarcoma and in the normal cells surrounding the tumor. Those cells […]
Team ASPS will bike the 2008 PMC: Please be generous and help us raise funds to find a cure for ASPS
Dear ASPS patients, family members and friends! Alveolar soft Part Sarcoma is a very rare cancer that attacks teenagers and young people. Unfortunately it does not respond to conventional therapies, such as radiation and chemotherapy. In 2004, the ASPS community established a team of bike riders as a tool to raise money for research on […]
Update: ARQ 197 – New Clinical Trial for Patients with Alveolar Soft Part Sarcoma
Previously, we reported that Alveolar Soft Part Sarcoma is a candidate for therapy by drugs that inhibit the MET receptor tyrosine kinase. Then, we reported the opening of a clinical trial of such an inhibitor, ARQ 197, in California. This clinical trial is now open in many more locations in the USA, and may soon be available in […]
iCureASPS supports ASPS Research in the laboratory of Dr. Dina Lev at MD Anderson Cancer Center
iCureASPS is looking for active members of the ASPS community to help maintaining viable collaborations with scientists who perform ASPS research in medical centers. If you wish to be part of an active search for Alveolar Soft Part Sarcoma Cure, please contact us! Such a new collaboration was recently established with Dr. Dina Lev at […]
iCureASPS Sponsors Studies on Halofuginone, a Possible Therapy for Alveolar Soft Part Sarcoma
iCureASPS has recently sent funds to sponsor an original research, which is carried out in the laboratory of Dr. Mark Pines at the Volcani Center, Bet Dagan, Israel. Halofuginone is an analog of the molecule febrifugine. Febrifugine is the active component in the extract from the roots of the Chinese herb chang shan (Dichroa febrifuga), […]
Two New Research Studies on Alveolar Soft Part Sarcoma
Two scientific publications on Alveolar Soft Part Sarcoma have been recently published: “Angiogenesis-promoting gene patterns in Alveolar Soft Part Sarcoma†by Lazar et al., 2007 (from M. D. Anderson Cancer Center) and “Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of Alveolar Soft Part Sarcoma†by Vistica et al., 2008 (from The National Cancer Center). Lazar […]
Team ASPS biked the 2007 PMC and raised funds to find a cure for ASPS
In the first week of August 2007, Team ASPS participated in the Pan-Massachusetts Challenge (PMC) bike ride for the fourth time. This bike-a-thon crosses Massachusetts to raise money for cancer research and treatment at the Dana-Farber Cancer Institute (DFCI) in Boston. Some of our riders rode 90 miles and others rode 150 miles. The money […]
ARQ 197: New Clinical Trial for Patients with Alveolar Soft Part Sarcoma
Update on the ARQ 197 Clinical Trial (November 23): The new clinical trial (read below) is now open and at least two ASPS patients are already participating in it. If you are interested to join the trial please read the information below and contact Dr. Isett Laux, the study coordinator for this study. Tel: 310-633 […]